The big biotech financing chill isn’t necessarily thawing after three years, but companies at least are finding creative ways to warm shareholders.
An example: Genentech Inc.’s deal Monday with Forma Therapeutics. The “asset acquisition” deal is a unique way of putting money in the hands of Cambridge, Mass.-based Forma’s backers — including the likes of Lilly Ventures and Bio-One Capital of Singapore — while giving South San Francisco-based Genentech control over development of a potential cancer treatment.
No comments:
Post a Comment